Return to homepagePandemic Pact

Characterizing the respiratory tract immune response after nasal COVID-19 vaccination

Grant number: 49697.1 IP-LS

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2021

  • Known Financial Commitments (USD)

    $459,818.7

  • Funder

    Innosuisse

  • Principal Investigator

    Amiq Gazdhar

  • Research Location

    Switzerland

  • Lead Research Institution

    Insel Gruppe AG, Bern

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Characterizing the nasal COVID-19 vaccine-induced immune responses in the blood, nose and lungs of young and mid-age adult rats to confirm the virosomes-RBD vaccine safety, tolerate, while eliciting protective respiratory immunity to block nasal infection and virus spreading to the lungs and brain.